
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
UGT2B10 CRISPR/Cas9 KO Plasmid (h) | sc-404210 | 20 µg | $397.00 |
UGT2B10 encodes a human UDP-glucuronosyltransferase that catalyzes glucuronidation reactions, increasing the solubility and facilitating clearance of endogenous metabolites and xenobiotics. As a phase II metabolic enzyme, UGT2B10 contributes to hepatic and extrahepatic detoxification pathways that regulate small-molecule homeostasis and chemical defense responses. Variation or altered expression of UGT2B10 can shift glucuronide conjugate profiles, impacting pharmacokinetics, metabolite-driven signaling, and cellular stress responses. These properties make UGT2B10 relevant to studies of drug metabolism, environmental exposure biology, and metabolic dysregulation associated with disease phenotypes.
UGT2B10 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the UGT2B10 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the UGT2B10 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the UGT2B10 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish UGT2B10 protein expression.
This CRISPR knockout system enables efficient generation of UGT2B10-deficient cell models for investigation of UGT2B10 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
CRISPRs +/- HDRs
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.